Authors: Ayumu Hosokawa Toshiro Sugiyama Atsushi Ohtsu Toshihiko Doi Santa Hattori Takashi Kojima Tomonori Yano Keiko Minashi Manabu Muto Shigeaki Yoshida
Publish Date: 2007/07/25
Volume: 42, Issue: 7, Pages: 533-538
Abstract
S1 an oral fluoropyrimidine has been shown to have excellent activity against gastric cancer in two phase II studies and is widely used in Japan However the longterm outcomes of patients after S1 monotherapy for metastatic gastric cancer are unclear The aim of this study was to investigate the longterm outcomes in metastatic gastric cancer patients who had initially received S1 monotherapyNinetytwo previously untreated patients with advanced gastric cancer received S1 monotherapy as firstline chemotherapy at the National Cancer Center Hospital East Kashiwa Japan and then the longterm outcomes and characteristics of longterm survivors were analyzed retrospectively Multivariate analysis of prognostic factors was performed by the Cox proportional hazard methodWith a median followup of 31 years the median progressionfree survival time was 46 months The median survival time was 119 months with 1 2 and 3year survival rates of 491 228 and 98 respectively Multivariate analysis showed that good performance status P = 00004 and only one metastatic site P = 00048 were significant independent prognostic factors Among 48 patients with a single metastatic site 22 with peritoneal metastasis had longer survival times median survival 24 months than patients with metastasis at other sites Among the nine 3year survivors six had peritoneal metastases aloneThe survival outcomes after S1 monotherapy are promising especially in patients with good performance status and a single metastatic site Our findings suggest that among patients with a single metastatic site those with peritoneal metastases alone have a chance for longterm survival
Keywords: